5 Best Covid Vaccine and Pill Stocks To Invest In

3. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 67    

Pfizer Inc. (NYSE:PFE) develops and sells perhaps the most famous COVID-19 vaccine around the world. The vaccine was recently approved for children aged 5-11 years-old as well. The company has a market cap of more than $245 billion. Authorities in the European Union recently approved the use of a simpler regimen for Vocabria, a drug developed by the firm along with GlaxoSmithKline, in treatment of HIV patients. 

Morgan Stanley analyst Matthew Harrison recently maintained an Equal Weight rating on Pfizer Inc. (NYSE:PFE) stock and raised the price target to $48 from $45, noting the broader adoption of the COVID-19 vaccine of the firm. 

At the end of the second quarter of 2021, 67 hedge funds in the database of Insider Monkey held stakes worth $2.3 billion in Pfizer Inc. (NYSE:PFE), up from 65 in the preceding quarter worth $2 billion.

In its Q1 2021 investor letter, ClearBridge Investments, an asset management firm, highlighted a few stocks and Pfizer Inc. (NYSE:PFE) was one of them. Here is what the fund said:

“Our underweights in health care and staples contributed to relative performance during the period. As we continue to focus the portfolio on high-conviction ideas, we sold Pfizer in late 2020, in the health care sector.”